Future of st jude medical

Company profile

Future of St. Jude Medical

DATA ACCESS

Access full data behind this profile

| Quantumrun Global 1000

St. Jude Medical, Inc. was a US worldwide medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had several major operations and production facilities globally with products sold in different countries. Its major markets include the Europe, Asia-Pacific, the United States, and Latin America. The company was named after Jude the Apostle, the patron saint of lost causes. St. Jude Medical was established in 1976 and went public in 1977. The company was bought and owned by Abbott Laboratories in January 2017.

Home Country:

United States

Sector:

Healthcare

Industry:

Medical Products and Equipment

Website:

St. Jude Medical

Founded:

1976

Global employee count:

18000

Domestic employee count:

Number of domestic locations:

Financial Health

3y average revenue:

$5,581,500,000 USD

3y average expenses:

$1,867,000,000 USD

Funds in reserve:

$667,000,000 USD

Market country

United States

Revenue from country

0.51%

Revenue from country

0.25%

Asset Performance

Product/Service/Dept. name
ICD systems
Product/Service revenue
$1,582,000,000 USD
USD
Product/Service/Dept. name
Atrial fibrillation products
Product/Service revenue
$1,096,000,000 USD
USD
Product/Service/Dept. name
Pacemaker systems
Product/Service revenue
$941,000,000 USD
USD

Innovation assets and Pipeline

Investment into R&D:

$676000000 USD

Total patents held:

1,257

Number of patents field last year:

All company data collected from its 2015 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page.

DISRUPTION VULNERABILITY

Belonging to the healthcare sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:

*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations. *However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on subsidized health services (hospitals, emergency care, nursing homes, etc.) to support them in their greying years.

*The economic strain caused this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs, surgeries and treatment protocols that may improve the overall physical and mental health of patients to a point where they can lead independent lives outside of the health care system.

*This increased investment into the health care system will include a greater emphasis on preventative medicine and treatments.

*By the early 2030s, the most profound preventative health care treatment will become available: treatments to stunt and later reverse the effects of aging. These treatments will be provided annually and, over time, will become affordable to the masses. This health revolution will result in a reduced usage and strain on the overall health care system—since younger people/bodies use less health care resources, on average, than people in older, sicker bodies.

*Increasingly, we will use artificial intelligence systems diagnose patients and robots to manage intricate surgeries.

*By the late 2030s, technological implants will correct any physical injury, while brain implants and memory erasure drugs will cure most any mental trauma or illness.

*By the mid-2030s, all medicines will be customized to your unique genome and microbiome.